CSF proteome analysis in clinically isolated syndrome (CIS): Candidate markers for conversion to definite multiple sclerosis

Neuroscience Letters

Volumn 452, Issue 2, 2009, Pages 214-217

  Tumani, H ^a   Lehmensiek, V ^a   Rau, D ^a   Guttmann, I ^a   Tauscher, G ^a   Mogel, H ^a   Palm, C ^a   Hirt, V ^a   Suessmuth, S D ^a   Sapunova Meier, I ^a   Ludolph, A C ^a   Brettschneider, J ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Cerebrospinal fluid; Clinically isolated syndrome; Difference in gel electrophoresis; Multiple sclerosis; Prognostic marker; Proteome

Indexed keywords

ALPHA1 GLYCOPROTEIN; ALPHA2 GLYCOPROTEIN; APOLIPOPROTEIN A4; COPPER ZINC SUPEROXIDE DISMUTASE; ENZYME INHIBITOR; FETUIN A; HAPTOGLOBIN; PROTEOME; RETINOL BINDING PROTEIN; SERIN PEPTIDASE INHIBITOR; SERINE; TRANSFERRIN; UNCLASSIFIED DRUG; ZINC ALPHA 2 GLYCOPROTEIN;

ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICALLY ISOLATED SYNDROME; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RELAPSE; REMISSION; SYNDROME; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION STUDY;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID PROTEINS; DEMYELINATING DISEASES; DISEASE PROGRESSION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; YOUNG ADULT;

EID: 60249090585     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.01.057     Document Type: Article

References (22)

1. Barkhof F., Filippi M., Miller D.H., Scheltens P., Campi A., Polman C.H., Comi G., Ader H.J., Losseff N., and Valk J. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120 Pt 11 (1997) 2059-2069
2. Berkova N., Gilbert C., Goupil S., Yan J., Korobko V., and Naccache P.H. TNF-induced haptoglobin release from human neutrophils: pivotal role of the TNF p55 receptor. J. Immunol. 162 (1999) 6226-6232
3. Brettschneider J., Mogel H., Lehmensiek V., Ahlert T., Sussmuth S., Ludolph A.C., and Tumani H. Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochem. Res. 33 (2008) 2358-2363
4. Brettschneider J., Petzold A., Junker A., and Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult. Scler. 12 (2006) 143-148
5. Chiasserini D., DiFilippo M., Candeliere A., Susta F., Orvietani P.L., Calabresi P., Binaglia L., and Sarchielli P. CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. Eur. J. Neurol. 15 (2008) 998-1001
6. Heiss A., Eckert T., Aretz A., Richtering W., van Dorp W., Schafer C., and Jahnen-Dechent W. Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J. Biol. Chem. 283 (2008) 14815-14825
7. Korteweg T., Tintore M., Uitdehaag B., Rovira A., Frederiksen J., Miller D., Fernando K., Filippi M., Agosta F., Rocca M., Fazekas F., Enzinger C., Matthews P., Parry A., Polman C., Montalban X., and Barkhof F. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol. 5 (2006) 221-227
8. Kuhle J., Pohl C., Mehling M., Edan G., Freedman M.S., Hartung H.P., Polman C.H., Miller D.H., Montalban X., Barkhof F., Bauer L., Dahms S., Lindberg R., Kappos L., and Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N. Engl. J. Med. 356 (2007) 371-378
9. Lebreton J.P., Joisel F., Raoult J.P., Lannuzel B., Rogez J.P., and Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J. Clin. Invest. 64 (1979) 1118-1129
10. Lehmensiek V., Sussmuth S.D., Brettschneider J., Tauscher G., Felk S., Gillardon F., and Tumani H. Proteome analysis of cerebrospinal fluid in Guillain-Barre syndrome (GBS). J. Neuroimmunol. 185 (2007) 190-194
11. Lehmensiek V., Sussmuth S.D., Tauscher G., Brettschneider J., Felk S., Gillardon F., and Tumani H. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult. Scler. 13 (2007) 840-849
12. Marouga R., David S., and Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal. Bioanal. Chem. 382 (2005) 669-678
13. Miller D., Barkhof F., Montalban X., Thompson A., and Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis. Part I. Natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 4 (2005) 281-288
14. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., and Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58 (2005) 840-846
15. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta 310 (2001) 173-186
16. Sato H., Kazama J.J., Wada Y., Kuroda T., Narita I., Gejyo F., Gao P., and Yamashita H. Decreased levels of circulating alpha2-Heremans-Schmid glycoprotein/Fetuin-A (AHSG) in patients with rheumatoid arthritis. Intern. Med. 46 (2007) 1685-1691
17. Swanton J.K., Rovira A., Tintore M., Altmann D.R., Barkhof F., Filippi M., Huerga E., Miszkiel K.A., Plant G.T., Polman C., Rovaris M., Thompson A.J., Montalban X., and Miller D.H. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 6 (2007) 677-686
18. Szweras M., Liu D., Partridge E.A., Pawling J., Sukhu B., Clokie C., Jahnen-Dechent W., Tenenbaum H.C., Swallow C.J., Grynpas M.D., and Dennis J.W. alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J. Biol. Chem. 277 (2002) 19991-19997
19. Thrower B.W. Clinically isolated syndromes: predicting and delaying multiple sclerosis. Neurology 68 (2007) S12-15
20. Tseng C.F., Lin C.C., Huang H.Y., Liu H.C., and Mao S.J. Antioxidant role of human haptoglobin. Proteomics 4 (2004) 2221-2228
21. Tumani H., Teunissen C., Sussmuth S., Otto M., Ludolph A.C., and Brettschneider J. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev. Mol. Diagn. 8 (2008) 479-494
22. Wagner L., Gessl A., Parzer S.B., Base W., Waldhausl W., and Pasternack M.S. Haptoglobin phenotyping by newly developed monoclonal antibodies. Demonstration of haptoglobin uptake into peripheral blood neutrophils and monocytes. J. Immunol. 156 (1996) 1989-1996